Skip to main content

Pramipexole

In Restless Legs Syndrome

Abstract

▴ Pramipexole is an oral, non-ergoline dopamine agonist with selectivity for the dopamine D3 receptor, which was recently approved in the EU and the US for the treatment of idiopathic restless legs syndrome (RLS) in adults.

▴ In a polysomnographic study, pramipexole 0.125, 0.25, 0.50 or 0.75mg once daily for 3 weeks significantly reduced from baseline the periodic limb movement index compared with placebo (−27 to-53 vs −3).

▴ Pramipexole at a median dosage of 0.35 mg/day for 6 weeks significantly reduced from baseline the mean International RLS Study Group rating scale (IRLS) score compared with placebo (−12.4 vs −6.1) and produced a significantly higher response (‘much improved’ or ‘very much improved’) rate (63% vs 33%) according to the Clinical Global Impressions-Improvement (CGI-I) scale.

▴ In a controlled-withdrawal study in which responders to pramipexole following 6 months’ therapy were randomised to pramipexole or placebo for 12 weeks, significantly less pramipexole than placebo recipients reached the target event of predefined worsening of symptoms (21% vs 86%).

▴ Treatment with pramipexole 0.25, 0.50 or 0.75mg once daily for 12 weeks significantly reduced IRLS scores from baseline values (−13 to −14 vs −9) and produced significantly higher proportions of CGI-I responders (68–75% vs 51%) compared with placebo.

▴ Pramipexole was generally well tolerated, with most adverse events being transient and of mild to moderate severity.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004 May 1; 27(3): 560–83

    PubMed  Google Scholar 

  2. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003 Mar; 4(2): 101–19

    PubMed  Article  Google Scholar 

  3. Allen RP. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007 Jan; 120(1 Suppl. 1): S13–21

    PubMed  Article  Google Scholar 

  4. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006 Oct; 13(10): 1049–65

    PubMed  Article  CAS  Google Scholar 

  5. Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease. Drugs Aging 1998 Jun; 12(6): 495–514

    PubMed  Article  CAS  Google Scholar 

  6. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol 1998; 21(3): 141–51

    PubMed  CAS  Google Scholar 

  7. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995 Jun 23; 290(1): 29–36

    PubMed  Article  CAS  Google Scholar 

  8. Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of renal impairment and hemodialysis on pramipexole pharmacokinetics [abstract no. P249]. Mov Disord 1997; 12Suppl. 1: 66

    Google Scholar 

  9. Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of probenecid and cimetidine on pramipexole pharmacokinetics [abstract no. PII-99]. Clin Pharmacol Ther 1996 Feb; 59(2): 183

    Article  Google Scholar 

  10. Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of age and gender on pramipexole pharmacokinetics [abstract no. PII-100]. Clin Pharmacol Ther 1996 Feb; 59(2): 184

    Article  Google Scholar 

  11. Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997 Jun; 37(6): 520–5

    PubMed  CAS  Google Scholar 

  12. Boehringer Ingelheim International GmbH. Mirapexin (pramipexole dihydrochloride monohydrate): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jan 25]

  13. Boehringer Ingelheim Pharmaceuticals Inc. Mirapex® (pramipexole dihydrochloride): US prescribing information [online]. Available from URL: http://bidocs.boehringeringelheim.com [Accessed 2007 Jan 31]

  14. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study—the PRELUDE study. Sleep Med 2006 Aug; 7(5): 407–17

    PubMed  Article  Google Scholar 

  15. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006 Sep 26; 67(6): 1034–9

    PubMed  Article  CAS  Google Scholar 

  16. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. The German RLS-Pramipexole Study Group. Mov Disord 2006 Sep; 21(9): 1404–10

    Google Scholar 

  17. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). The Pramipexole RLS Study Group. Mov Disord 2007 Jan 15; 22(2): 213–9

    Article  Google Scholar 

  18. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Acute placebocontrolled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002 Aug; 252(4): 185–94

    PubMed  CAS  Google Scholar 

  19. Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999 Mar 23; 52(5): 938–43

    PubMed  Article  CAS  Google Scholar 

  20. Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006 Dec; 13(12): 1306–11

    PubMed  Article  CAS  Google Scholar 

  21. Emura N, Kuroda K, Inoue Y, et al. Effects of pramipexole on sleep parameters during a randomized, controlled trial in Japanese patients with restless legs syndrome [abstract no. P403]. Mov Disord 2006 Jan; 21Suppl. 15: S438

    Google Scholar 

  22. Mathis J, Bassetti C. Comparison of pramipexole versus levodopa/benserazide in the treatment of restless legs syndrome: a double blind, randomized, Swiss multi-centre crossover trial. Swiss RLS Study Group [abstract no. P419]. Mov Disord 2006 Jan; 21Suppl. 15: S442

    Google Scholar 

  23. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. The International Restless Legs Syndrome Study Group. Sleep Med 2003 Mar; 4(2): 121–32

    Google Scholar 

  24. Stiasny-Kolster K, Oertel W. Pramipexole-an effective treatment option in restless legs syndrome patients with depressed mood [abstract no. P195]. Mov Disord 2005; 20Suppl. 10: S59. Plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)

    Google Scholar 

  25. Partinen M, Hirvonen K, Jama L, et al. Sustained efficacy of pramipexole in restless legs syndrome: results from a 6-month extension of a 3-week trial [abstract no. P390]. Mov Disord 2006 Jan; 21Suppl. 15: S434

    Google Scholar 

  26. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Six-month efficacy of pramipexole for restless legs syndrome: results from a 20-week extension of a 6-week study [abstract no. P405]. Mov Disord 2006 Jan; 21Suppl. 15: S438

    Google Scholar 

  27. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Sustained effects of pramipexole on mood in patients with restless legs syndrome [abstract no. P1156]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2–5; Glasgow

  28. Inoue Y, Fujita M, Shimizu T, et al. Efficacy and safety of pramipexole in Japanese patients with restless legs syndrome [abstract no. P418]. Mov Disord 2006 Jan; 21Suppl. 15: S442

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul L. McCormack.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McCormack, P.L., Siddiqui, M.A.A. Pramipexole. CNS Drugs 21, 429–437 (2007). https://doi.org/10.2165/00023210-200721050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721050-00008

Keywords

  • Placebo Recipient
  • Pramipexole
  • Periodic Limb Movement
  • Periodic Limb Movement During Sleep
  • Coprimary Endpoint